Cas:1375064-69-9 Methyl 5-(2-Pyrazinyl)isoxazole-3-carboxylate manufacturer & supplier

Chemical Name:Methyl 5-(2-Pyrazinyl)isoxazole-3-carboxylate

CAS.NO:1375064-69-9

Synonyms:Methyl 5-(2-pyrazinyl)-1,2-oxazole-3-carboxylate

Molecular Formula:C₉H₇N₃O₃

Molecular Weight:205.17000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:78.11000

Exact Mass:205.04900

LogP:0.91820

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Methyl 5-(2-pyrazinyl)-1,2-oxazole-3-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Methyl 5-(2-pyrazinyl)-1,2-oxazole-3-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methyl 5-(2-pyrazinyl)-1,2-oxazole-3-carboxylate Use and application,Methyl 5-(2-pyrazinyl)-1,2-oxazole-3-carboxylate technical grade,usp/ep/jp grade.

Related News: This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? Methyl 5-(2-Pyrazinyl)isoxazole-3-carboxylate manufacturer More than 2,000 new cases were also recorded in the country in the past 24 hours, raising the worldwide total to nearly 14,380, according to Chinese and World Health Organization data. The vast majority of the cases are inside China; about 100 cases have been confirmed in at least 23 other countries. Methyl 5-(2-Pyrazinyl)isoxazole-3-carboxylate supplier Darzalex has its own VRd combo trials, dubbed PERSEUS and CEPHEUS, which are testing a newly approved under-the-skin version of the J&J drug called Darzalex Faspro. The CEPHEUS trial appears to have just completed its primary analysis, according to a listing on ClinicalTrials.gov. Methyl 5-(2-Pyrazinyl)isoxazole-3-carboxylate vendor More than 2,000 new cases were also recorded in the country in the past 24 hours, raising the worldwide total to nearly 14,380, according to Chinese and World Health Organization data. The vast majority of the cases are inside China; about 100 cases have been confirmed in at least 23 other countries. Methyl 5-(2-Pyrazinyl)isoxazole-3-carboxylate factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?